JP7387113B2 - New Lactobacillus lactic acid bacteria - Google Patents
New Lactobacillus lactic acid bacteria Download PDFInfo
- Publication number
- JP7387113B2 JP7387113B2 JP2022075280A JP2022075280A JP7387113B2 JP 7387113 B2 JP7387113 B2 JP 7387113B2 JP 2022075280 A JP2022075280 A JP 2022075280A JP 2022075280 A JP2022075280 A JP 2022075280A JP 7387113 B2 JP7387113 B2 JP 7387113B2
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- lactic acid
- acid bacteria
- cells
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims description 118
- 241000894006 Bacteria Species 0.000 title claims description 66
- 235000014655 lactic acid Nutrition 0.000 title claims description 59
- 239000004310 lactic acid Substances 0.000 title claims description 59
- 241000186660 Lactobacillus Species 0.000 title claims description 25
- 229940039696 lactobacillus Drugs 0.000 title claims description 25
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 36
- 239000002537 cosmetic Substances 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 23
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 description 51
- 230000014509 gene expression Effects 0.000 description 18
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 17
- 102100026720 Interferon beta Human genes 0.000 description 16
- 108090000467 Interferon-beta Proteins 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002519 immonomodulatory effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 239000012620 biological material Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 229940088592 immunologic factor Drugs 0.000 description 5
- 239000000367 immunologic factor Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- -1 IFN-λ3 Proteins 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 101150066749 Rnasel gene Proteins 0.000 description 3
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241001662087 Lactobacillus gasseri ATCC 33323 = JCM 1131 Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 239000006356 lactobacillus kefiranofaciens Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 108700021236 Antiviral Restriction Factors Proteins 0.000 description 1
- 102000054566 Antiviral Restriction Factors Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明は、ラクトバチルス・ガセリに分類される新規乳酸菌株及びその菌体を含有する食品、飼料、医薬品または化粧品に関するものである。 The present invention relates to a novel lactic acid bacteria strain classified as Lactobacillus gasseri and foods, feeds, pharmaceuticals, or cosmetics containing the bacteria.
乳酸菌は極めて高い安全性を有する微生物であり、ヨーグルトなどの発酵乳製品や各種漬物など多くの加工食品において、味や風味の付与、栄養の強化、食品の保存性改善をはじめとした様々な目的で用いられてきた。また、乳酸菌の病原体に対する感染防御作用といった生理活性について近年注目が集まっており、精力的に研究が進められている。 Lactic acid bacteria are extremely safe microorganisms, and are used in many processed foods, such as fermented dairy products such as yogurt and various pickles, for a variety of purposes, including adding taste and flavor, enhancing nutrition, and improving food preservation. It has been used in In addition, the physiological activities of lactic acid bacteria, such as their ability to protect against pathogens, have attracted attention in recent years, and research is actively underway.
免疫系において重要な役割を担っているマクロファージなどの免疫細胞は、ウイルス感染時に、ウイルス由来RNA鎖や表層に存在するエンベロープといった分子をToll-like receptorをはじめとしたパターン認識受容体によって認識し、インターフェロン(IFN)-βに代表されるI型IFN及びλ3に代表されるIII型IFNを産生することが知られている。 Immune cells such as macrophages, which play an important role in the immune system, recognize molecules such as virus-derived RNA chains and envelopes present on the surface during virus infection using pattern recognition receptors such as Toll-like receptors. It is known to produce type I IFN, represented by interferon (IFN)-β, and type III IFN, represented by λ3.
産生されたIFNは、周囲の細胞に発現するIFN受容体に結合する。刺激を受けた細胞は、細胞内シグナル経路の活性化を介して、抗ウイルスタンパク質として知られるRNaseLなどの発現を増強し、この結果として感染細胞周辺に強力な感染防御作用がもたらされる(非特許文献1)。したがって、ウイルスに対する感染を予防軽減するためには、IFN-βやRNaseL等の免疫因子の発現を促進する乳酸菌株が求められている。 The IFN produced binds to IFN receptors expressed on surrounding cells. Stimulated cells enhance the expression of RNaseL, which is known as an antiviral protein, through activation of intracellular signal pathways, resulting in a strong infection defense effect around infected cells (non-patent Reference 1). Therefore, in order to prevent and reduce viral infections, there is a need for lactic acid bacteria strains that promote the expression of immune factors such as IFN-β and RNaseL.
そこで、本発明は、高い免疫調節作用を有するラクトバチルス属に分類される新規乳酸菌株とその菌体を含有する食品、飼料、医薬品または化粧品を提供することを目的とする。 Therefore, an object of the present invention is to provide a novel lactic acid bacteria strain classified into the genus Lactobacillus that has a high immunomodulating effect, and foods, feeds, pharmaceuticals, or cosmetics containing the bacteria.
上記の課題を解決するため、本発明の発明者らは、ヒト由来の乳酸菌について検討を行った結果、特定の菌株にIFN-βやRNaseLをはじめとした免疫因子の発現を増強する等の高い免疫調節作用があることを見出し、本発明を完成させるに至った。 In order to solve the above problems, the inventors of the present invention investigated human-derived lactic acid bacteria and found that certain strains have high They discovered that it has an immunomodulatory effect and completed the present invention.
すなわち、本発明新規ラクトバチルス属乳酸菌は、以下の構成を有することを特徴とする。
(1) ラクトバチルス・ガセリTMT36株(受託番号:NITE P-03500)であるラクトバチルス属乳酸菌。
(2) ラクトバチルス・ガセリTMT39株(受託番号:NITE P-03501)であるラクトバチルス属乳酸菌。
(3) ラクトバチルス・ガセリTMT40株(受託番号:NITE P-03502)であるラクトバチルス属乳酸菌。
(4) 60℃以上の温度で加熱することによって製造する(1)~(3)のいずれかに記載のラクトバチルス属乳酸菌。
(5) (1)~(4)のいずれかに記載のラクトバチルス属乳酸菌を含有する医薬用組成物、食品用組成物、飼料用組成物または化粧料用組成物。
That is, the novel Lactobacillus lactic acid bacteria of the present invention is characterized by having the following structure.
(1) A lactic acid bacterium of the genus Lactobacillus, which is Lactobacillus gasseri TMT36 strain (accession number: NITE P-03500).
(2) A lactic acid bacterium of the genus Lactobacillus, which is Lactobacillus gasseri TMT39 strain (accession number: NITE P-03501).
(3) A lactic acid bacterium of the genus Lactobacillus, which is Lactobacillus gasseri TMT40 strain (accession number: NITE P-03502).
(4) The lactic acid bacteria of the genus Lactobacillus according to any one of (1) to (3), which is produced by heating at a temperature of 60° C. or higher.
(5) A pharmaceutical composition, food composition, feed composition, or cosmetic composition containing the Lactobacillus lactic acid bacteria according to any one of (1) to (4).
本発明新規ラクトバチルス属乳酸菌は、高い免疫調節作用を有することから、これを摂取することで生体の免疫が賦活化され、ウイルス感染症やその他免疫疾患等の予防及び/又は治療が可能となるという効果を有する。 The novel Lactobacillus lactic acid bacteria of the present invention have a high immunomodulatory effect, so ingesting them activates the immune system of the body, making it possible to prevent and/or treat viral infections and other immune diseases. It has this effect.
以下、本発明を実施するための形態について、詳細に説明する。
<新規ラクトバチルス属乳酸菌>
本発明に係るラクトバチルス属に属する新規乳酸菌は、ラクトバチルス・ガセリ(Lactobacillus gasseri)である。特に、ラクトバチルス・ガセリに属する乳酸菌のうち、ラクトバチルス・ガセリTMT36、39、40株である。
EMBODIMENT OF THE INVENTION Hereinafter, the form for implementing this invention is demonstrated in detail.
<New Lactobacillus lactic acid bacteria>
The novel lactic acid bacterium belonging to the genus Lactobacillus according to the present invention is Lactobacillus gasseri. In particular, among the lactic acid bacteria belonging to Lactobacillus gasseri, Lactobacillus gasseri TMT36, 39, and 40 strains are used.
本発明のラクトバチルス・ガセリTMT36、39、40株は、令和3年7月29日に独立行政法人製品技術基盤機構特許微生物寄託センターに NITE P―03500、NITE P―03501、NITE P―03502としてそれぞれ寄託されている。 The Lactobacillus gasseri TMT36, 39, and 40 strains of the present invention were transferred to the Patent Microorganism Depositary of the Japan Institute of Technology and Innovation on July 29, 2021, as NITE P-03500, NITE P-03501, and NITE P-03502. Both have been deposited as .
本発明のラクトバチルス・ガセリTMT36、39、40株の形態的特徴や生理的性状などは、以下の表1のとおりである。
生理的性状(糖資化性):当該菌株及びラクトバチルス・ガセリの標準株であるJCM1131T株の糖資化性は表2のとおりである。
表2において特筆すべきは、TMT36、39及び40株とJCM1131T株間で、D-Turanoseの資化性が異なる点である。当該菌株の生理的形質は標準株のそれとは完全に一致しないことから、TMT36、39及び40株は、新規の乳酸菌株であると判断した。 What should be noted in Table 2 is that the ability to assimilate D-Turanose differs between the TMT36, 39, and 40 strains and the JCM1131 T strain. Since the physiological characteristics of the strain did not completely match those of the standard strain, TMT36, 39, and 40 strains were determined to be new lactic acid bacteria strains.
本発明に係るラクトバチルス属に属する新規乳酸菌は、当該乳酸菌の菌体及び/又は菌体を含む培養物を有効成分としている。「菌体」とは本発明の新規乳酸菌の生菌体および死菌体のいずれも含む意味である。また、「菌体」は、本発明の新規乳酸菌の生菌体及び/又は死菌体を凍結乾燥などの乾燥処理した乾燥菌体であってもよく、培養液から単離した湿潤菌体であってよいし、生菌体及び/又は死菌体を破砕した菌体破砕物でもよいし、菌体成分でもよい。 The novel lactic acid bacterium belonging to the genus Lactobacillus according to the present invention uses cells of the lactic acid bacterium and/or a culture containing the cells as an active ingredient. The term "bacterial cells" includes both live and dead cells of the novel lactic acid bacteria of the present invention. In addition, "bacterial cells" may be dry microbial cells obtained by drying live and/or dead microbial cells of the novel lactic acid bacteria of the present invention such as freeze-drying, or wet microbial cells isolated from a culture solution. It may be a bacterial cell fragment obtained by crushing live and/or dead bacterial cells, or it may be a bacterial cell component.
一方、「培養物」とは、「菌体」を培養した培養液、及び、当該培養液に対して所定の処理を施した培養液処理物等を含む意味である。「菌体」の培養液に対する処理としては、特に限定されないが、乾燥処理、加熱処理、菌体死滅化処理、酵素処理、破砕処理、濾過処理、成分抽出処理等を挙げることができる。「培養物」としては、「菌体」の培養液そのもののみならず、当該培養液の凍結乾燥物、培養液の加熱処理物、培養液に対して放射線照射や抗生物質処理、化学物質処理した処理物、界面活性剤により細胞壁を溶解処理した処理物等が含まれる。「培養物」は、「菌体」を培養した培養液から生菌体または死菌体を除去した培養濾過液でもよいし、培養液から単離した「菌体」を懸濁した菌体懸濁液でもよい。「培養物」の形態としては、固形物、粉末状、顆粒状、ペースト状、液状などいずれであってもよい。 On the other hand, the term "culture" includes a culture solution in which "microbial cells" are cultured, a culture solution treated product obtained by subjecting the culture solution to a predetermined treatment, and the like. Treatments for the culture solution of "microbial cells" include, but are not particularly limited to, drying treatment, heating treatment, bacterial cell killing treatment, enzyme treatment, crushing treatment, filtration treatment, component extraction treatment, and the like. "Cultures" include not only the "bacterial cell" culture fluid itself, but also lyophilized culture fluids, heat-treated culture fluids, and culture fluids that have been irradiated, treated with antibiotics, or treated with chemicals. This includes treated products, processed products in which cell walls are dissolved using a surfactant, and the like. "Culture" may be a culture filtrate obtained by removing live or dead bacteria from a culture solution in which "bacterial cells" have been cultured, or a bacterial suspension in which "bacterial cells" isolated from a culture solution are suspended. A cloudy liquid may be used. The "culture" may be in any form such as solid, powder, granule, paste, or liquid.
本発明ラクトバチルス属乳酸菌は、単独で用いる事もできるし、2種以上の乳酸菌を組み合わせて用いてもよい。また、他の乳酸菌と併用してもよい。 The lactic acid bacteria of the genus Lactobacillus of the present invention can be used alone, or two or more types of lactic acid bacteria can be used in combination. It may also be used in combination with other lactic acid bacteria.
他の乳酸菌としては、特に限定されず、例えばラクトバチルス属(Lactobacillus)に属する従来公知の種を広く適用することができる。ラクトバチルス属(Lactobacillus)に属する微生物としては、例えば、ラクトバチルス・ガセリ(Lactobacillus gasseri)、ラクトバチルス・へルベティカス(Lactobacillus helveticus) 、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)、ラクトバチルス・デルブルッキー・亜種・ブルガリカス(Lactobacillus delbrueckii ssp.bulgaricus)、ラクトバチルス・ラムノーサス(Lactobacillus rhamnosus)、ラクトバチルス・ジョンソニー(Lactobacillus johnsonii)、ラクトバチルス・ロイテリ(Lactobacillus reuteri)、ラクトバチルス・アニマリス(Lactobacillus animalis)、ラクトバチルス・ラムノーサス(Lactobacillus rhamnosus)、ラクトバチルス・サリバリウス・亜種・サリバリウス(Lactobacillus salivarius ssp.salivarius)、ラクトバチルス・ケフィラノファシエンス(Lactobacillus kefiranofaciens)、ラクトバチルス・パラカゼイ(Lactobacillus paracasei)、ラクトバチルス・ファーメンタム(Lactobacillus fermentum)、ラクトバチルス・ケフィラノファシエンス(Lactobacillus kefiranofaciens)、ラクトバチルス・デルブルッキー・亜種・ラクティス(Lactobacillus delbrueckii ssp.lactis)、ラクトバチルス・アミロボラス(Lactobacillus amylovorus)、ラクトバチルス・ブクネリ(Lactobacillus buchneri)、ラクトバチルス・ゼアエ(Lactobacillus zeae)、ラクトバチルス・プランタラム(Lactobacillus plantarum)、ラクトバチルス・クリスパタス(Lactobacillus crispatus)等を挙げることができる。 Other lactic acid bacteria are not particularly limited, and for example, conventionally known species belonging to the genus Lactobacillus can be widely used. Examples of microorganisms belonging to the genus Lactobacillus include Lactobacillus gasseri, Lactobacillus helveticus, and Lactobacillus acidophilus. lus acidophilus), Lactobacillus delbrookii subsp.・Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus johnsonii Lactobacillus reuteri, Lactobacillus animalis, Lactobacillus・Lactobacillus rhamnosus, Lactobacillus salivarius subspecies ・Lactobacillus salivarius ssp. salivarius, Lactobacillus kefira nofaciens), Lactobacillus paracasei, Lactobacillus fermentum (Lactobacillus fermentum), Lactobacillus kefiranofaciens, Lactobacillus delbrueckii subspecies lactis (Lactobacillus delbrueckii ssp.lactis) ), Lactobacillus amylovorus, Lactobacillus buchneri buchneri), Lactobacillus zeae, Lactobacillus plantarum, Lactobacillus crispatus, and the like.
ラクトバチルス・ガセリTMT36(NITE P-03500)、TMT39(NITE P-03501)、TMT40(NITE P-03502)は優れた免疫調節作用を有する。特に、他のラクトバチルス・ガセリ(例えばラクトバチルス・ガセリJCM1131T等)に比べて、IFN-β、IFN-λ3、RNaseL等の免疫因子の発現誘導能が高いことを特徴とする。 Lactobacillus gasseri TMT36 (NITE P-03500), TMT39 (NITE P-03501), and TMT40 (NITE P-03502) have excellent immunomodulatory effects. In particular, compared to other Lactobacillus gasseri (eg, Lactobacillus gasseri JCM1131 T , etc.), it is characterized by a high ability to induce the expression of immune factors such as IFN-β, IFN-λ3, and RNaseL.
本発明の乳酸菌は、乳酸菌培養の常法に従って任意の条件で培養することができる。培養方法については特に限定されず、従来公知の方法を適宜選択して使用することができる。 The lactic acid bacteria of the present invention can be cultured under any conditions according to conventional methods for culturing lactic acid bacteria. The culture method is not particularly limited, and conventionally known methods can be appropriately selected and used.
培養温度は一般的に20~43℃が望ましく、37~39℃がより望ましいが、菌が生育する温度であれば他の温度条件でも良い。培養中の培地のpHは3.0~8.0に維持することが望ましく、5.5~5.8に維持することがより望ましいが、菌が生育するpHであれば他のpH条件でも良い。培養時間は通常12~72時間が好ましいが、菌が生育することができる時間であれば、他の培養時間でも良い。乳酸菌を培養するための培地としては、特に限定されないが、乳酸菌の培養に通常用いられる培地が使用される。すなわち、主炭素源のほか窒素源、無機物質、その他の栄養素を程よく含有する培地ならばいずれの培地も使用可能である。炭素源としては、グルコース、ラクトース、スクロース、フルクトース、デンプン加水分解物、廃糖蜜等が使用できる。窒素源としてはカゼインの加水分解物、大豆タンパク質の加水分解物、馬鈴薯の加水分解物などが使用できる。他に増殖促進剤として肉エキス、魚肉エキス、酵母エキス、オレイン酸などが用いられる。 The culture temperature is generally preferably 20 to 43°C, more preferably 37 to 39°C, but other temperature conditions may be used as long as the temperature allows the bacteria to grow. The pH of the medium during cultivation is preferably maintained at 3.0 to 8.0, more preferably 5.5 to 5.8, but other pH conditions may be used as long as the pH allows the bacteria to grow. good. The culture time is usually preferably 12 to 72 hours, but other culture times may be used as long as the time allows the bacteria to grow. The medium for culturing lactic acid bacteria is not particularly limited, but a medium commonly used for culturing lactic acid bacteria can be used. That is, any medium can be used as long as it contains a sufficient amount of nitrogen sources, inorganic substances, and other nutrients in addition to the main carbon source. As the carbon source, glucose, lactose, sucrose, fructose, starch hydrolyzate, blackstrap molasses, etc. can be used. As the nitrogen source, casein hydrolyzate, soybean protein hydrolyzate, potato hydrolyzate, etc. can be used. Other growth promoters that can be used include meat extract, fish extract, yeast extract, and oleic acid.
特に、本発明に係るラクトバチルス・ガセリ(Lactobacillus gasseri)TMT36、TMT39およびTMT40株の菌体及び/又はその培養物は、加熱処理を施すことが好ましい。加熱処理を施したこれらの乳酸菌の菌体及び/又はその培養物による免疫因子の発現は、加熱処理する前と比較して大きく増強される。これにより、加熱処理を施した上記各乳酸菌の菌体及び/又はその培養物には、ウイルス感染症やその他免疫疾患等を予防軽減に導くより優れた効果が期待できる。 In particular, the cells of Lactobacillus gasseri TMT36, TMT39 and TMT40 strains and/or the culture thereof according to the present invention are preferably subjected to heat treatment. The expression of immune factors by the heat-treated lactic acid bacteria cells and/or their culture is greatly enhanced compared to before the heat treatment. As a result, the heat-treated cells of each of the lactic acid bacteria and/or their culture can be expected to have superior effects in preventing and alleviating viral infections and other immune diseases.
加熱処理としては、特に限定されないが、60℃以上の温度で加熱することが好ましく、80~100℃の温度で加熱することが特に好ましい。 The heat treatment is not particularly limited, but heating at a temperature of 60°C or higher is preferable, and heating at a temperature of 80 to 100°C is particularly preferable.
また、加熱処理時間は、加熱温度や圧力等の条件によって異なるが、例えば0.1~60分間が好ましく、5分間~40分間がより好ましい。 Further, the heat treatment time varies depending on conditions such as heating temperature and pressure, but is preferably 0.1 to 60 minutes, more preferably 5 minutes to 40 minutes.
<医薬用組成物>
本発明に係る乳酸菌は、一例として医薬用組成物に適用することができる。医薬用組成物としては、特に限定されないが、生理学的に許容された担体、賦形剤、結合剤、希釈剤などと混合することにより製剤化して使用することができる。具体的に、本発明に係る医薬用組成物の剤形としては、例えば、錠剤、丸剤、散剤、液剤、懸濁剤、乳剤、顆粒剤、カプセル剤、シロップ剤、坐剤、注射剤、軟膏剤、貼付剤、点眼剤、および点鼻剤などを挙げることができる。製剤化に当たっては、製剤担体として通常使用される賦形剤、結合剤、崩壊剤、潤沢剤、安定剤、嬌味嬌臭剤、希釈剤、界面活性剤、または注射剤用溶剤等の添加剤を使用することができる。
<Pharmaceutical composition>
The lactic acid bacteria according to the present invention can be applied to pharmaceutical compositions, for example. Although the pharmaceutical composition is not particularly limited, it can be formulated and used by mixing it with physiologically acceptable carriers, excipients, binders, diluents, and the like. Specifically, the dosage forms of the pharmaceutical composition according to the present invention include, for example, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories, injections, Examples include ointments, patches, eye drops, and nasal drops. When formulating, additives such as excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, or solvents for injections that are commonly used as pharmaceutical carriers are used. can be used.
特に、本発明に係る乳酸菌を使用した医薬用組成物は、経口的または非経口的に投与することができる。経口剤としては、顆粒剤、散剤、錠剤(糖衣錠を含む。)、丸剤、カプセル剤、シロップ剤、乳剤、懸濁剤が挙げられる。非経口剤としては、外用剤(例えば、経鼻製剤、経皮製剤、軟膏剤)、坐剤(例えば、直腸坐剤、膣坐剤)が挙げられる。また、本発明に係る乳酸菌を使用した医薬用組成物は、他の医薬、例えば免疫賦活剤等を併用してもよく、当該医薬用組成物の投与時期は特に限定されない。 In particular, the pharmaceutical composition using the lactic acid bacteria according to the present invention can be administered orally or parenterally. Oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions. Parenteral preparations include external preparations (for example, nasal preparations, transdermal preparations, ointments) and suppositories (for example, rectal suppositories, vaginal suppositories). Furthermore, the pharmaceutical composition using the lactic acid bacteria according to the present invention may be used in combination with other medicines, such as immunostimulants, and the timing of administration of the pharmaceutical composition is not particularly limited.
<食品用組成物>
本発明に係る乳酸菌の用途は、食品用組成物(ヒト用)にも適用することができる。食品用組成物としては、特に限定されず、例えば、健康食品、機能性食品、特定保健用食品及び栄養補助食品(サプリメント)などを挙げることができる。食品用組成物の具定例として、ジュース、清涼飲料水、茶飲料、ドリンク剤、ゼリー状飲料及び機能性飲料等の各種飲料;蒸留酒、清酒及びビール等のアルコール飲料;米飯類、麺類、パン類及びパスタ類等の炭水化物含有食品;カマボコ及び竹輪等の水産練り製品;ハム及びソーセージ等の畜産加工品;カレー、あんかけ及び中華スープ等のレトルト製品;スープ類;牛乳、乳飲料、アイスクリーム、チーズ及びヨーグルト等の乳製品;みそ、納豆、乳酸菌発酵飲料及び漬物等の発酵製品;豆製品、ビスケット及びクッキーなどの洋菓子類;饅頭及び羊羹等の和菓子類;キャンディー類;ガム類;グミ、ゼリー及びプリンなどの冷菓や氷菓などの菓子類;インスタントスープ及びインスタントみそ汁等のインスタント食品;電子レンジ対応食品;マヨネーズ、ドレッシング及び味付け調味料液等の調味料を挙げることができる。
<Food composition>
The use of the lactic acid bacteria according to the present invention can also be applied to food compositions (for humans). Food compositions are not particularly limited, and include, for example, health foods, functional foods, foods for specified health uses, and nutritional supplements. Specific examples of food compositions include various beverages such as juices, soft drinks, tea drinks, drinks, jelly drinks, and functional drinks; alcoholic beverages such as distilled spirits, sake, and beer; cooked rice, noodles, and bread. carbohydrate-containing foods such as rice cakes and pasta; seafood paste products such as kamaboko and chikuwa; processed livestock products such as ham and sausage; retort products such as curry, ankake and Chinese soup; soups; milk, milk drinks, ice cream, and cheese and dairy products such as yogurt; fermented products such as miso, natto, lactic acid bacteria fermented drinks and pickles; Western confectionery such as bean products, biscuits and cookies; Japanese confectionery such as manju and yokan; candies; gums; gummies, jellies and Confectionery such as frozen desserts and frozen desserts such as pudding; instant foods such as instant soup and instant miso soup; foods that can be microwaved; and seasonings such as mayonnaise, dressing, and flavored seasoning liquid.
<飼料用組成物>
一方、本発明に係る乳酸菌の用途としては、上述したヒト用の食品用組成物に限定されず、ヒトを除く動物に対して与える飼料用組成物(飼料又は飼料添加物)を挙げることができる。ここで飼料とは、ヒトを除く動物に供される食物(ペットフードを含む。)を意味し、飼料添加物とはヒトを除く動物用のサプリメントを含む意味である。
<Feed composition>
On the other hand, the uses of the lactic acid bacteria according to the present invention are not limited to the above-mentioned human food compositions, but can include feed compositions (feeds or feed additives) given to animals other than humans. . Feed herein means food (including pet food) provided to animals other than humans, and feed additives include supplements for animals other than humans.
飼料を供する対象の動物としては、脊椎動物、具体的にはヒトを除く哺乳動物、例えば、霊長類(サル、チンパンジー等)、家畜動物(ウシ、ウマ、ブタ、ヒツジ、家禽類等)、ペット動物(「愛がん動物」ともいう)(イヌ、ネコ等)、実験動物(マウス、ラット等)、競技用動物(ウマ等)、その他、爬虫類、鳥類(ニワトリ等)、甲殻類(エビ、カニ等)、昆虫類(コオロギ、バッタ等)等がある。 Animals to be fed include vertebrates, specifically mammals other than humans, such as primates (monkeys, chimpanzees, etc.), livestock animals (cows, horses, pigs, sheep, poultry, etc.), and pets. Animals (also called "pet animals") (dogs, cats, etc.), laboratory animals (mice, rats, etc.), competition animals (horses, etc.), other reptiles, birds (chickens, etc.), crustaceans (shrimp, crabs, etc.) ), insects (crickets, grasshoppers, etc.), etc.
また、飼料は、上述した乳酸菌の他に、トウモロコシ粉、米粉、糠などの穀粉、粕類、糠類、魚粉、骨粉、油脂類、脱脂粉乳、ホエー、鉱物質飼料、酵母類、無機質、アミノ酸、タンパク質、ビタミン類、脂質などを含んでいても良い。具体的には、日本標準飼料成分表(2009年版、農業・食品産業技術総合研究機構編)に記載されるような成分が含まれていても良い。 In addition to the lactic acid bacteria mentioned above, feeds include corn flour, rice flour, rice bran and other grain flours, lees, bran, fish meal, bone meal, fats and oils, skim milk powder, whey, mineral feed, yeast, minerals, and amino acids. , proteins, vitamins, lipids, etc. Specifically, the ingredients listed in the Japan Standard Feed Composition Table (2009 edition, edited by the National Agriculture and Food Research Organization) may be included.
さらに、飼料用組成物は、例えば、タブレット状や粉末状の剤形として動物用、特にペット動物のサプリメントとしても良い。 Furthermore, the feed composition may be used as a supplement for animals, particularly pet animals, in the form of tablets or powders, for example.
あるいは、本発明に係る飼料は、青刈り作物や生の牧草等の飼料作物をサイロに詰め、上述した乳酸菌(一例としてラクトバチルス・ガセリTMT36、TMT39及び/又はTMT40株)により乳酸発酵させたサイレージであってもよい。 Alternatively, the feed according to the present invention is a silage obtained by filling a silo with feed crops such as cut green crops or fresh grass and performing lactic acid fermentation with the above-mentioned lactic acid bacteria (for example, Lactobacillus gasseri TMT36, TMT39 and/or TMT40 strains). It may be.
<化粧料用組成物>
本発明に係る乳酸菌は、化粧料用組成物にも適用することができる。
「化粧料」とは、皮膚や粘膜等の上皮組織に接触させることにより、所望の効果を達成する、皮膚や粘膜に対して使用する製剤をいう。特に長時間継続的に皮膚や粘膜に接触させる用途に本発明は有効である。
<Composition for cosmetics>
The lactic acid bacteria according to the present invention can also be applied to cosmetic compositions.
"Cosmetics" refers to preparations for use on the skin or mucous membranes that achieve a desired effect by contacting epithelial tissues such as the skin or mucous membranes. The present invention is particularly effective in applications where the composition is brought into continuous contact with the skin or mucous membranes for a long period of time.
本発明による化粧料用組成物は化粧料に配合されるが、配合対象となる化粧料については特に制限はなく、たとえば、化粧水、美容液、乳液、クリーム、ファンデーション、アイシャドウ、口紅、頬紅、エモリエントクリーム、エモリエントローション、クリーム、クリームリンス、コールドクリーム、バニッシングクリーム、ローション、パック剤、ジェル、フェイスパック、石けん、ボディーソープ、シャンプー、コンディショナー、リンス、洗顔料、シェービングクリーム、ヘアクリーム、ヘアローション、ヘアートリートメント、髪パック、グロス、リップクリーム、ケーキ等の皮膚又は毛髪用化粧料、練歯磨、湿潤歯磨、液状歯磨、洗口剤、口中清涼剤などの口腔用化粧料が挙げられる。 The cosmetic composition according to the present invention is blended into cosmetics, but there are no particular restrictions on the cosmetics to which it can be blended, such as lotion, serum, milky lotion, cream, foundation, eye shadow, lipstick, and blusher. , emollient cream, emollient lotion, cream, cream rinse, cold cream, vanishing cream, lotion, pack agent, gel, face pack, soap, body soap, shampoo, conditioner, conditioner, facial cleanser, shaving cream, hair cream, hair lotion , skin or hair cosmetics such as hair treatments, hair packs, glosses, lip balms, and cakes, and oral cosmetics such as toothpastes, moist toothpastes, liquid toothpastes, mouthwashes, and mouth fresheners.
また、化粧品も化粧料に含まれる。化粧品としては、清浄用化粧品、頭髪用化粧品、基礎化粧品、メークアップ化粧品、芳香化粧品、日焼け用化粧品、日焼け止め用化粧品、爪化粧品、アイライナー化粧品、アイシャドウ化粧品、チーク、口唇化粧品、口腔化粧品などに分類され、そのいずれの用途にも本発明は有効である。 Cosmetics are also included in cosmetics. Cosmetics include cleansing cosmetics, hair cosmetics, basic cosmetics, makeup cosmetics, aromatic cosmetics, sunburn cosmetics, sunscreen cosmetics, nail cosmetics, eyeliner cosmetics, eyeshadow cosmetics, cheeks, lip cosmetics, oral cosmetics, etc. The present invention is effective for any of these applications.
さらに、化粧料は、医薬品又は医薬部外品であってもよい。例えば、薬学的に有効な成分を含む軟膏に本発明による化粧料組成物を配合することもできる。 Furthermore, the cosmetic may be a drug or a quasi-drug. For example, the cosmetic composition according to the present invention can be incorporated into an ointment containing pharmaceutically effective ingredients.
本発明の乳酸菌は、医薬用、食品用、飼料及び/又は化粧料用組成物に加工・配合させて使用する場合、該乳酸菌の配合割合は特に限定されず、製造の容易性や好ましい一日投与・使用量にあわせて適宜調節すればよい。投与・使用対象者の症状、年齢、体重、用途等を考慮してそれぞれ個別に決定されるが、通常成人の場合、該乳酸菌の培養物などを一日当たり1~200g、菌体自体を一日当たり1.0×1010個~1.0×1011個、あるいは乾燥重量として0 .001~90%になるように配合量などを調整すればよく、このようにして摂取することにより所望の効果を発揮することができる。 When the lactic acid bacteria of the present invention is processed and blended into pharmaceutical, food, feed, and/or cosmetic compositions, the blending ratio of the lactic acid bacteria is not particularly limited, and the ratio of the lactic acid bacteria is not particularly limited. The dosage may be adjusted as appropriate depending on the administration and usage amount. This is determined individually taking into consideration the symptoms, age, weight, intended use, etc. of the person to be administered and used, but for adults, the usual dosage is 1 to 200 g of the lactic acid bacteria culture per day, and the bacterial cells themselves per day. The blending amount may be adjusted to 1.0×10 10 to 1.0×10 11 or 0.001 to 90% as dry weight, and by ingesting it in this way, the desired effect can be achieved. can demonstrate.
以下に、実施例として試験例及び処方例を示し、本発明についてより詳細に説明するが、これらは単に例示するのみであり、本発明はこれらによって何ら限定されるものではない。 The present invention will be explained in more detail below by showing test examples and prescription examples as examples, but these are merely illustrative and the present invention is not limited by these.
<試験例1>
新規乳酸菌のIFN-β及びRNaseL遺伝子発現促進作用
1-1.試験方法
(1)新規乳酸菌の菌体調製
ラクトバチルス・ガセリに属する各菌株をMRS培地(Difco)に接種し、37℃で16時間培養した。培養後、滅菌0.15 M塩化ナトリウム-0.01 Mリン酸緩衝液(PBS、pH 7.2)で3回洗浄し、菌数が2.5×109個/mLになるようにPBSで懸濁した。
(2)試験手順
次に、ブタ肺胞マクロファージ(3D4/31細胞)をRPMI-1640培地(Wako社)で2.0×105個/mLになるように懸濁し、これを12穴プレートの各ウェルに1mLずつ播種し、一晩培養した。培地交換後に菌体を5.0×107個/mLとなるように添加し、2日間培養した。コントロールとして、PBSを添加したwell(図中では、with poly(I:C)と表記)を作製した。培養後、100ng/mLとなるようにRNAウイルスの模倣物質であるpoly(I:C)を添加したRPMI-1640培地に交換後、3および12時間培養した。
刺激終了後、PBSで2回洗浄し、各wellにTRIzol reagent(Invitrogen)を添加して細胞溶解液を回収し、フェノール-クロロホルム抽出、エタノール沈殿にてRNAを抽出した。得られたRNAからPrimeScript RT reagent Kit(タカラバイオ社)を用いてcDNAを合成した。
得られたcDNAを鋳型として、Platinum SYBR Green qPCR Super Mix-UDG with ROX(Invitrogen)を用いた定量的Real-time PCR(qPCR)法によりIFN-β及びRNaseLの遺伝子発現解析を行なった。
<Test Example 1>
IFN-β and RNaseL gene expression promoting effect of novel lactic acid bacteria 1-1. Test method (1) Preparation of new lactic acid bacteria cells Each strain belonging to Lactobacillus gasseri was inoculated into MRS medium (Difco) and cultured at 37°C for 16 hours. After culturing, the cells were washed three times with sterile 0.15 M sodium chloride-0.01 M phosphate buffer (PBS, pH 7.2) and diluted with PBS so that the number of bacteria was 2.5 x 10 9 cells/mL. It was suspended in
(2) Test procedure Next, porcine alveolar macrophages (3D4/31 cells) were suspended in RPMI-1640 medium (Wako) to a concentration of 2.0 x 10 cells/mL, and this was placed in a 12-well plate. 1 mL of each well was seeded and cultured overnight. After replacing the medium, bacterial cells were added at 5.0 x 10 7 cells/mL and cultured for 2 days. As a control, a well to which PBS was added (denoted as with poly(I:C) in the figure) was prepared. After culturing, the medium was replaced with RPMI-1640 medium supplemented with poly(I:C), an RNA virus mimic, at a concentration of 100 ng/mL, and cultured for 3 and 12 hours.
After stimulation, the cells were washed twice with PBS, TRIzol reagent (Invitrogen) was added to each well, the cell lysate was collected, and RNA was extracted by phenol-chloroform extraction and ethanol precipitation. cDNA was synthesized from the obtained RNA using PrimeScript RT reagent Kit (Takara Bio Inc.).
Using the obtained cDNA as a template, gene expression analysis of IFN-β and RNaseL was performed by quantitative real-time PCR (qPCR) using Platinum SYBR Green qPCR Super Mix-UDG with ROX (Invitrogen). .
1-2.試験結果
図1は、新規乳酸菌の中からIFN-β及びRNaseLの発現促進作用を有する菌株を選抜するために、ラクトバチルス・ガセリに属する乳酸菌を3D4/31細胞に添加し、IFN-β及びRNaseLの遺伝子発現量を解析した結果である。
poly(I:C)による3時間および12時間の刺激に対して、ラクトバチルス・ガセリTMT36、TMT39及びTMT40株は、IFN-β及びRNaseLの発現誘導能が他の株と比較して強いことが示された。
1-2. Test results Figure 1 shows that in order to select strains that have the effect of promoting the expression of IFN-β and RNaseL from among new lactic acid bacteria, lactic acid bacteria belonging to Lactobacillus gasseri were added to 3D4/31 cells, and IFN-β and RNaseL were added to 3D4/31 cells. This is the result of analyzing the gene expression level of .
When stimulated with poly(I:C) for 3 hours and 12 hours, Lactobacillus gasseri TMT36, TMT39, and TMT40 strains have a stronger ability to induce IFN-β and RNaseL expression than other strains. Shown.
<試験例2>
加熱処理したラクトバチルス・ガセリTMT36、TMT39及びTMT40株のIFN-β及びRNaseL遺伝子発現促進作用
1-1.試験方法
(1)加熱処理菌体の調製
試験例1に記載の培養方法に従って培養したラクトバチルス・ガセリTMT36、TMT39及びTMT40株を65、90または121℃で30分間加熱処理後、菌数が2.5×109個/mLになるようにPBSで懸濁した。
(2)試験手順
試験例1に記載の試験手順に従って、各加熱条件で調整したTMT36、TMT39またはTMT40株を3D4/31細胞に添加し、2日間培養後、poly(I:C)で刺激した。
刺激終了後、cDNAを合成し、qPCR法によりIFN-β及びRNaseLの遺伝子発現解析を行なった。
<Test Example 2>
Effect of heat-treated Lactobacillus gasseri TMT36, TMT39 and TMT40 on promoting IFN-β and RNaseL gene expression 1-1. Test method (1) Preparation of heat-treated bacterial cells Lactobacillus gasseri TMT36, TMT39, and TMT40 strains cultured according to the culture method described in Test Example 1 were heat-treated at 65, 90, or 121°C for 30 minutes, and the number of bacteria decreased to 2. The cells were suspended in PBS to a concentration of .5×10 9 cells/mL.
(2) Test procedure According to the test procedure described in Test Example 1, TMT36, TMT39, or TMT40 strains prepared under each heating condition were added to 3D4/31 cells, cultured for 2 days, and then stimulated with poly(I:C). .
After the stimulation was completed, cDNA was synthesized and gene expression analysis of IFN-β and RNaseL was performed by qPCR method.
1-2.試験結果
図2は、当該菌株が有するIFN-β及びRNaseL遺伝子発現誘導能における加熱特性を検討するために、加熱処理したラクトバチルス・ガセリTMT36、TMT39及びTMT40株を添加した3D4/31細胞におけるIFN-β及びRNaseLの遺伝子発現量を生菌体と比較解析した結果である。
全ての当該菌株に関して、加熱処理菌体のIFN-β及びRNaseLの発現誘導能は生菌体と比較して同等以上だった。とりわけ、90℃/30分間の加熱処理を行なった場合、総じてIFN-β及びRNaseLの発現誘導能が増強されることが示された。
1-2. Test results Figure 2 shows the effects of IFN-β in 3D4/31 cells to which heat-treated Lactobacillus gasseri TMT36, TMT39, and TMT40 strains were added in order to examine the heating characteristics of the strain in its ability to induce IFN-β and RNaseL gene expression. This is the result of comparative analysis of the gene expression levels of -β and RNaseL with that of live bacterial cells.
Regarding all the strains, the ability to induce the expression of IFN-β and RNaseL in the heat-treated cells was equal to or higher than that in the live cells. In particular, it was shown that the ability to induce the expression of IFN-β and RNaseL was generally enhanced when heat treatment was performed at 90° C. for 30 minutes.
<試験例3>
加熱処理菌体と標準株の免疫調節能に関する比較
1-1.試験方法
(1)加熱処理菌体の調製
試験例1に記載の培養方法に従って、培養したラクトバチルス・ガセリTMT36、TMT39及びTMT40株を90℃で30分間加熱処理後、菌数が2.5×109個/mLになるようにPBSで懸濁した。また、同様の条件で加熱処理したラクトバチルス・ガセリJCM1131Tを対照区として用いた。なお、図中では、加熱処理をHT(Heat-treated)と記載した。
(2)試験手順
試験例1に記載の試験手順に従って、加熱処理を施したTMT36、TMT39またはTMT40株の菌体を3D4/31細胞に添加し、2日間培養後、poly(I:C)で刺激した。
刺激終了後、cDNAを合成し、qPCR法により各種免疫因子の発現解析を行なった。
<Test Example 3>
Comparison of immunomodulatory ability of heat-treated bacterial cells and standard strain 1-1. Test method (1) Preparation of heat-treated bacterial cells According to the culture method described in Test Example 1, the cultured Lactobacillus gasseri TMT36, TMT39, and TMT40 strains were heat-treated at 90°C for 30 minutes, and the number of bacteria was 2.5×. The cells were suspended in PBS to a concentration of 10 9 cells/mL. In addition, Lactobacillus gasseri JCM1131 T , which had been heat-treated under the same conditions, was used as a control. Note that in the figure, the heat treatment is indicated as HT (Heat-treated).
(2) Test procedure According to the test procedure described in Test Example 1, heat-treated TMT36, TMT39, or TMT40 strain cells were added to 3D4/31 cells, and after culturing for 2 days, poly(I:C) It stimulated me.
After the stimulation was completed, cDNA was synthesized and the expression of various immune factors was analyzed by qPCR.
1-2.試験結果
図3は、加熱処理したラクトバチルス・ガセリTMT36、TMT39及びTMT40株とラクトバチルス・ガセリの標準株であるJCM1131T株の免疫調節能を比較解析した結果である。
全ての当該加熱処理菌体は、poly(I:C)のみと比較して、各種免疫因子(IFN-β、IFN-λ3及びRNaseL)を増強し、その活性は標準株であるJCM1131T株よりも高かった。以上の結果から、ラクトバチルス・ガセリTMT36、TMT39及びTMT40株による免疫調節作用は、他のラクトバチルス・ガセリよりも優れていることが示された。
1-2. Test Results FIG. 3 shows the results of a comparative analysis of the immunomodulatory ability of heat-treated Lactobacillus gasseri TMT36, TMT39, and TMT40 strains and JCM1131 T strain, a standard strain of Lactobacillus gasseri.
All of the heat-treated bacterial cells enhanced various immune factors (IFN-β, IFN-λ3, and RNaseL) compared to poly(I:C) alone, and their activity was higher than that of the standard strain JCM1131 T strain. It was also expensive. The above results showed that the immunomodulatory effects of Lactobacillus gasseri TMT36, TMT39, and TMT40 strains were superior to those of other Lactobacillus gasseri strains.
<処方例1>
ラクトバチルス・ガセリTMT36含有医薬用組成物(顆粒)の製造
ラクトバチルス・ガセリTMT36株を食用可能な合成培地(0.5% 酵母エキス、0.1% トリプチケースペプトン添加) に5重量%接種し、38℃で15時間培養後、遠心分離で菌体を回収した。回収した菌体を凍結乾燥し、前記菌体の凍結乾燥粉末を得た。この凍結乾燥粉末1gを乳糖5gと混合し、顆粒状に成形して本発明の医薬用組成物(顆粒)を得た。
<Prescription example 1>
Production of Lactobacillus gasseri TMT36-containing pharmaceutical composition (granules) Lactobacillus gasseri TMT36 strain was inoculated at 5% by weight into an edible synthetic medium (added with 0.5% yeast extract and 0.1% trypticase peptone). After culturing at 38°C for 15 hours, the bacterial cells were collected by centrifugation. The collected cells were freeze-dried to obtain a freeze-dried powder of the cells. 1 g of this freeze-dried powder was mixed with 5 g of lactose and formed into granules to obtain the pharmaceutical composition (granules) of the present invention.
<処方例2>
ラクトバチルス・ガセリTMT39含有医薬用組成物(散剤)の製造
第13改正日本薬局方解説書製剤総則「散剤」の規定に準拠し、上記処方例1と同様の方法で得られたラクトバチルス・ガセリTMT39株の凍結乾燥粉末10gに乳糖(日局)400g、バレイショデンプン(日局)600gを加えて均一に混合し、本発明の医薬用組成物(顆粒)を得た。
<Prescription example 2>
Manufacture of Lactobacillus gasseri TMT39-containing pharmaceutical composition (powder) Lactobacillus gasseri obtained in accordance with the provisions of the 13th revised Japanese Pharmacopoeia Explanation General Rules for Preparations "Powder" and in the same manner as in Prescription Example 1 above. 400 g of lactose (Japanese Pharmacopoeia) and 600 g of potato starch (Japanese Pharmacopoeia) were added to 10 g of freeze-dried powder of TMT39 strain and mixed uniformly to obtain a pharmaceutical composition (granules) of the present invention.
<処方例3>
ラクトバチルス・ガセリTMT40含有食品用組成物(ゼリー)の製造
上記処方例1と同様の方法で得られたラクトバチルス・ガセリTMT40株20g、果糖2,000 g 、グラニュー糖1,500g、水飴500g、寒天100g、香料10g、脱イオン水5,870gを混合し、TKホモミクサー(TK ROBO MICS;特殊機化工業社製)にて、6,000rpmで10分間撹拌混合し、50℃ に加熱して溶解した後、100gずつ容器へ充填して冷却することで、本発明の食品用組成物(ゼリー)を得た。
<Prescription example 3>
Production of Lactobacillus gasseri TMT40-containing food composition (jelly) 20 g of Lactobacillus gasseri TMT40 strain obtained in the same manner as in Formulation Example 1 above, 2,000 g of fructose, 1,500 g of granulated sugar, 500 g of starch syrup, Mix 100 g of agar, 10 g of fragrance, and 5,870 g of deionized water, stir and mix at 6,000 rpm for 10 minutes using a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.), and then heat to 50°C to dissolve. After that, the food composition (jelly) of the present invention was obtained by filling 100 g into containers and cooling.
<処方例4>
ラクトバチルス・ガセリTMT36含有食品用組成物(清涼飲料水)の製造
上記処方例1と同様の方法で得られたラクトバチルス・ガセリTMT36株200mg、50%乳酸0.75kg、エリスリトール5.7kg、香料1kg、脱イオン水42.55kgを混合し、40℃ まで加熱後、TKホモミクサー(TK ROBO MICS;特殊機化工業社製)にて、6,000rpmで10分間撹拌混合した。この溶液を90℃で10分間殺菌後10℃以下まで冷却することで、本発明の食品用組成物(清涼飲料水)を得た。
<Prescription example 4>
Production of Lactobacillus gasseri TMT36-containing food composition (soft drink) 200 mg of Lactobacillus gasseri TMT36 strain obtained in the same manner as in Formulation Example 1 above, 0.75 kg of 50% lactic acid, 5.7 kg of erythritol, fragrance 1 kg of deionized water and 42.55 kg of deionized water were mixed, heated to 40° C., and stirred and mixed for 10 minutes at 6,000 rpm using a TK homomixer (TK ROBO MICS; manufactured by Tokushu Kika Kogyo Co., Ltd.). The food composition (soft drink) of the present invention was obtained by sterilizing this solution at 90° C. for 10 minutes and then cooling it to 10° C. or lower.
<処方例5>
ラクトバチルス・ガセリTMT39含有飼料用組成物の製造
大豆粕12kg、脱脂粉乳14kg、大豆油4kg、コーン油2kg、パーム油23.2kg、トウモロコシ澱粉14kg、小麦粉9kg、ふすま2kg、ビタミン混合物5kg、セルロース2.8kg、ミネラル混合物2kgを配合し、120℃、4分間殺菌して、処方例1と同様の方法で得られたラクトバチルス・ガセリTMT39株10kgを配合して、本発明の飼料用組成物を得た。
<Prescription example 5>
Production of feed composition containing Lactobacillus gasseri TMT39 Soybean meal 12 kg, skim milk powder 14 kg, soybean oil 4 kg, corn oil 2 kg, palm oil 23.2 kg, corn starch 14 kg, wheat flour 9 kg, bran 2 kg, vitamin mixture 5 kg, cellulose 2 The feed composition of the present invention was prepared by blending 10 kg of Lactobacillus gasseri TMT39 strain obtained in the same manner as Formulation Example 1 by blending . Obtained.
本発明新規ラクトバチルス属乳酸菌は、高い免疫調節作用を有することから、これを摂取することで生体の免疫が賦活化され、ウイルス感染症やその他免疫疾患等の予防及び/又は治療が可能となり、これを医薬品、食品、飼料、化粧料等に応用することができるものである。 The novel Lactobacillus lactic acid bacteria of the present invention have a high immunomodulatory effect, so ingesting them activates the immune system of the living body, making it possible to prevent and/or treat viral infections and other immune diseases. This can be applied to medicines, foods, feeds, cosmetics, etc.
[寄託生物材料への言及]
1.ラクトバチルス・ガセリTMT36
イ 当該生物材料を寄託した寄託機関の名称及び住所
独立行政法人 製品評価技術基盤機構 特許微生物センター
日本国千葉県木更津市かずさ鎌足2-5-8 122号室(郵便番号292-0818)
ロ イの寄託機関に生物材料を寄託した日付
令和3年7月29日
ハ イの寄託機関が寄託について付した受託番号
NITE P-03500
2.ラクトバチルス・ガセリTMT39
イ 当該生物材料を寄託した寄託機関の名称及び住所
独立行政法人 製品評価技術基盤機構 特許微生物センター
日本国千葉県木更津市かずさ鎌足2-5-8 122号室(郵便番号292-0818)
ロ イの寄託機関に生物材料を寄託した日付
令和3年7月29日
ハ イの寄託機関が寄託について付した受託番号
NITE P-03501
3.ラクトバチルス・ガセリTMT40
イ 当該生物材料を寄託した寄託機関の名称及び住所
独立行政法人 製品評価技術基盤機構 特許微生物センター
日本国千葉県木更津市かずさ鎌足2-5-8 122号室(郵便番号292-0818)
ロ イの寄託機関に生物材料を寄託した日付
令和3年7月29日
ハ イの寄託機関が寄託について付した受託番号
NITE P-03502
[Reference to deposited biological material]
1. Lactobacillus gasseri TMT36
(a) Name and address of the depositary institution that deposited the biological material concerned: National Institute of Technology and Evaluation (Independent Administrative Agency) Patent Microorganisms Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818)
Date of deposit of biological materials with the Depository of Japan July 29, 2021 Accession number NITE P-03500 given by the Depository of Japan regarding the deposit
2. Lactobacillus gasseri TMT39
(a) Name and address of the depositary institution that deposited the biological material concerned: National Institute of Technology and Evaluation (Independent Administrative Agency) Patent Microorganisms Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818)
Date of deposit of biological materials with the Depository of Japan July 29, 2021 Accession number NITE P-03501 given by the Depository of Japan regarding the deposit
3. Lactobacillus gasseri TMT40
(a) Name and address of the depositary institution that deposited the biological material concerned: National Institute of Technology and Evaluation (Independent Administrative Agency) Patent Microorganisms Center Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818)
Date of deposit of biological materials with the Depository of Japan July 29, 2021 Accession number NITE P-03502 given by the Depository of Japan regarding the deposit
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022075280A JP7387113B2 (en) | 2022-04-28 | 2022-04-28 | New Lactobacillus lactic acid bacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022075280A JP7387113B2 (en) | 2022-04-28 | 2022-04-28 | New Lactobacillus lactic acid bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023164002A JP2023164002A (en) | 2023-11-10 |
JP7387113B2 true JP7387113B2 (en) | 2023-11-28 |
Family
ID=88651598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022075280A Active JP7387113B2 (en) | 2022-04-28 | 2022-04-28 | New Lactobacillus lactic acid bacteria |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7387113B2 (en) |
-
2022
- 2022-04-28 JP JP2022075280A patent/JP7387113B2/en active Active
Non-Patent Citations (1)
Title |
---|
Kawase, Manabu, et al.,"Heat-killed Lactobacillus gasseri TMC0356 protects mice against influenza virus infection by stimulating gut and respiratory immune responses.",FEMS Immunology & Medical Microbiology,2011年12月05日,vol.64.2,pp.280-288 |
Also Published As
Publication number | Publication date |
---|---|
JP2023164002A (en) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11759486B2 (en) | Lactobacillus plantarum and composition comprising same | |
US11447740B2 (en) | Lactic acid bacterium and use thereof | |
JP6685974B2 (en) | Novel lactic acid bacterium having IgA production promoting action and use thereof | |
JP5791009B2 (en) | Lactic acid bacteria and food or drink using them | |
JP5273695B2 (en) | Allergy prevention and / or treatment agent containing bifidobacteria as an active ingredient | |
KR101355770B1 (en) | Method for culture of lactic acid bacterium having high immunomodulating activity | |
JP6290080B2 (en) | New lactic acid bacteria | |
JP5001830B2 (en) | Immunostimulating composition | |
JP6894097B2 (en) | Composition for improving renal anemia | |
KR101995328B1 (en) | Lactobacillus fermentum WiKim0102 having anti-cancer activity and composition for comprising the same | |
JP6551934B2 (en) | Bifidobacterium and / or lactic acid bacteria growth promoter and / or suppressor | |
JP7090288B2 (en) | New lactic acid bacteria, innate immune activators containing new lactic acid bacteria as active ingredients, and foods and drinks containing new lactic acid bacteria | |
JP6675703B1 (en) | Lactic acid bacteria, natural immunity activators derived from the lactic acid bacteria, infectious disease preventive / therapeutic agents, and food and drink | |
TW201609120A (en) | Intestinal barrier function enhancer containing lactic acid bacteria | |
JP6894096B2 (en) | Composition for promoting cartilage regeneration | |
JP7387113B2 (en) | New Lactobacillus lactic acid bacteria | |
JP2019167327A (en) | Iii type interferon production promoting composition containing bifidobacterium bacteria as active ingredient | |
JP7448483B2 (en) | Lactobacillus plantarum species lactic acid bacteria isolated from carp sushi and its screening method | |
KR102143615B1 (en) | Novel Kazachstania turicensis CAU Y1706, and compositions using the same | |
JP7067827B1 (en) | Interferon production promoter | |
TW202335676A (en) | Intestine immunostimulant and IgA generation promoter for ensuring Apilactobacillus lactobacillus having IgA generation promotion effect and immunostimulation function | |
KR20240072335A (en) | Lactiplantibacillus plantarum WiKim0146 with anti-inflammatory effect and uses thereof | |
JP5851242B2 (en) | Lactic acid bacteria having thioredoxin-inducing activity, and foods and beverages and pharmaceuticals for preventing and / or improving biological injury mediated by thioredoxin | |
TW202419100A (en) | Composition for improving intestinal barrier function and enhancing intestinal epithelial tight junction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7387113 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |